Comparison of inhaled mannitol, daily rhDNase, and a combination of both in children with cystic fibrosis: a randomised trial

Caro Minasian, MRCPCH 1, Colin Wallis, FRCPCH, MD 2,
Chris Metcalfe, PhD 3, Andrew Bush, FRCPCH, MD 1

1 Royal Brompton Hospital & Imperial College, London, UK

2 Great Ormond Street Hospital, London, UK

3 University of Bristol, Bristol, UK

Correspondence: Caro Minasian
Department of Paediatric Respiratory Medicine,
Royal Brompton Hospital,
Sydney Street, London SW3 6NP, UK
Tel: 0207 351 8283
Fax: 0207 351 8763
E mail: carominasian@hotmail.com

Short Title: Comparison of inhaled mannitol & rhDNase in children with cystic fibrosis

Keywords: mannitol, rhDNase, cystic fibrosis, osmotic, trial

Word count: 3000 words
The Corresponding Author has the right to grant on behalf of all authors and
does grant on behalf of all authors, an exclusive licence (or non exclusive for
government employees) on a worldwide basis to the BMJ Publishing Group Ltd and
its Licensees to permit this article (if accepted) to be published in [THORAX]
editions and any other BMJPG Ltd products to exploit all subsidiary rights, as
set out in our licence

(http://group.bmj.com/products/journals/instructions-for-authors/licence-
forms).
Abstract

Background
Osmotic agents, such as inhaled dry powder mannitol may increase mucociliary clearance (MCC) by rehydrating the airway-surface liquid (ASL) and thus act as disease-modifying treatments in cystic fibrosis (CF). This is the first therapeutic trial of inhaled mannitol in children with CF. We have compared it to human recombinant deoxyribonuclease (rhDNase), the current best established mucolytic therapy.

Methods
38 children were recruited to an open crossover study. Subjects underwent an initial bronchial provocation challenge with dry powder mannitol. Those children with a negative challenge were randomly allocated to one of three consecutive twelve-week treatment blocks (inhaled mannitol alone, nebulised rhDNase alone and mannitol + rhDNase). The primary outcome was forced expiratory volume in 1 second (FEV$_1$). A number of secondary outcome measures were also studied.

Results
Twenty children completed the study. Bronchoconstriction and cough associated with mannitol administration contributed to the high attrition rate. The mean increase in FEV$_1$ following 12 weeks of treatment was 0.11 litres (6.7%) (p=0.055) for mannitol alone, 0.12 litres (7.2%) (p=0.03) for rhDNase alone & 0.03 litres (1.88%) (p=0.67) for rhDNase and mannitol. None of the secondary clinical outcomes were statistically significantly different between treatments.
Conclusions

Inhaled mannitol was at least as effective as rhDNase after 3 months treatment. There was a marked individual variation in tolerance to mannitol and in response to therapy however. Children who do not respond to rhDNase many benefit from a trial of inhaled mannitol. The combination of mannitol and rhDNase was not useful.
Introduction

Many processes contribute to airway obstruction and progressive lung damage in cystic fibrosis (CF), including the production of abnormally viscid mucus, mucus hypersecretion and defective mucociliary clearance (MCC). Previous therapeutic approaches aimed at improving airway clearance have included suppression or eradication of bacterial infection and attenuation of inflammation. Mucolytic agents have also been used to reduce sputum viscosity. Human recombinant deoxyribonuclease (rhDNase) is a now a well established and widely used adjunctive therapy for CF. Deoxyribonucleic acid (DNA) derived from neutrophil degradation is present in very high concentrations in the sputum of patients with CF and is a major contributor to the viscosity of airway secretions. rhDNase cleaves this extracellular DNA improving mucus rheology. Several studies have now clearly demonstrated improvements in lung function and fewer chest exacerbations in patients treated with rhDNase. [1-3] It may also reduce neutrophilic airway inflammation. [4] There is widespread variation in the individual responses to rhDNase [3,5] however and a significant number of patients derive no clinical benefit.

Epithelial airway-surface liquid (ASL) volume regulation is critical for normal MCC and airway dehydration is now thought to be a key initiating event in the pathogenesis of CF lung disease. [6-9] There has been recent interest in osmotically active agents which may potentially increase MCC by rehydrating the ASL and thus act as disease-modifying therapies in CF. Two recent studies have demonstrated a modest increase in forced expiratory volume in 1 second (FEV\textsubscript{1}) and fewer pulmonary exacerbations in CF patients treated with nebulised hypertonic saline (HS). [10,11] Inhaled dry powder mannitol represents another novel osmotic agent. Mannitol is a naturally
occurring sugar alcohol which is stable as a dry powder and suitable for encapsulation. It has been widely used as a bronchial provocation agent in measuring bronchial responsiveness. [12-14] A number of studies have also demonstrated a beneficial effect of inhaled mannitol on MCC in patients with bronchiectasis and CF. [15-18] To date there has been one study examining the effect of mannitol in lung function in CF. [19] This short term safety and efficacy trial reported that it was well-tolerated and improved lung function over a two-week period. The current study represents the first therapeutic trial of dry powder mannitol in children with CF. We have compared it to rhDNase, the current best-established mucolytic therapy and tested the hypothesis that inhaled mannitol, alone or in combination with rhDNase is as effective as rhDNase in improving respiratory function in children with CF.

Methods

Study population

Children with a diagnosis of CF on standard criteria [20] were recruited from two institutions (The Royal Brompton & Harefield NHS Trust, London, UK and Great Ormond Street Hospital for Children NHS Trust, London, UK). Inclusion criteria were age between 8 and 18 years, the ability to perform repeatable reliable spirometry (according to American Thoracic Society criteria [21]) and either currently receiving rhDNase treatment or an FEV₁ of > 40% and <70% predicted normal value (and therefore judged eligible to receive rhDNase). Exclusion criteria were known hypersensitivity to mannitol, rhDNase or bronchodilators, sputum infection with methicillin-resistant staphylococcus aureus (MRSA) or Burkholderia cepacia, portal
hypertension or varices, significant haemoptysis (>60mls) in the previous 12 months, breast-feeding or pregnancy. In addition, in order to ensure clinical stability at enrolment, patients had to have no changes in therapy or new respiratory symptoms in the two weeks prior to study entry.

The study protocol was approved by the local research ethics committee and full written carer and child age-appropriate consent was obtained prior to trial entry. The trial was registered with ClinicalTrials.gov (Identifier NCT00117208).

**Study design and procedures**

We conducted a prospective, randomised, open-label, crossover study. All subjects underwent a bronchial provocation challenge with dry powder mannitol prior to study entry. [22] Children were pre-treated with bronchodilator, following which they received incrementally increasing doses of mannitol up to a maximum cumulative dose of 475mg. FEV₁ was measured at the start of the challenge and after each increase in dose. A positive challenge was defined as a fall of ≥15% in FEV₁ from baseline. These children were withdrawn from the main study. Subjects with a negative challenge were randomly allocated to one of three consecutive 12-week treatment blocks (mannitol alone, rhDnase alone and a combination of mannitol and rhDNase). There was a two-week washout period during which patients already on rhDNase therapy discontinued it. In order to prevent a carry-over effect between treatment periods there was also a two-week washout period between treatment blocks. Previous studies have shown that two weeks is sufficient washout for the effects of rhDNase to disappear. [3,5] Any longer than this may have lead to a clinical
deterioration related to stopping mucolytic therapy in those patients in whom it was established treatment prior to study entry. All other concomitant therapy was continued during the study.

Spray-dried dry powder mannitol was pre-packaged into gelatin capsules (40mg per-capsule) and administered via a breath-activated inhaler device (Osmohaler™). Patients were instructed on inhaler technique and all manoeuvres during study visits were supervised by the study investigator. Subjects inhaled 400mg (10 capsules) twice a day. All children were pre-treated with their usual bronchodilator (400mcg of Salbutamol or 1mg of Terbutaline) 15 minutes prior to inhalation of the mannitol. 2.5 mg of rhDNase (Pulmozyme, Roche Products, UK) was administered through the patient’s normal nebuliser device twice a day.

The total study period was 41 weeks, subjects attending for seven visits. They were assessed at the start and end of each 12-week treatment period. Bronchodilators and physiotherapy were withheld for 4 hours prior to each visit.

**Outcome measures**

The protocol-defined primary outcome was FEV$_1$. Secondary outcome measures were forced vital capacity (FVC) and forced expiratory flow (FEF$_{25-75}$), frequency of pulmonary exacerbations, sputum microbiology, exercise tolerance, quality of life scores and adverse events. At every visit, lung function was measured in accordance with American Thoracic Society guidelines [21] using a hand-held compact spirometer (Vitalograph 2120, Vitalograph UK), which was calibrated with a 1 litre syringe prior to each visit. Flow volume loops were inspected and confirmed as satisfactory and three measurements taken to ensure repeatability. To minimise the
effect of normal diurnal variation in lung function, >70% of study visits were at the same time of day.

Exercise tolerance was assessed by subjects performing a 3 minute step test at each visit. Standard age-appropriate validated quality of life (CFQ-R) questionnaires were completed by the children and additionally parent/guardian in those under 14. Subjects also completed respiratory symptom and treatment effect questionnaires at each visit. Sputum was collected for microbiology at the start and end of each treatment block on all those children able to spontaneously expectorate. Cough swabs were taken for the remaining children.

Information on adverse events was collected at every visit from the patient-held study diaries given to all participants at the start of the study. Treatment adherence was assessed by asking all subjects to return unused mannitol capsules and empty vials rhDNase.

Statistical analysis

A sample size of 42 children would allow a mean difference in FEV₁ of 0.1 litres (about 8%) between treatments to be detected with 90% power at the 5% significance level, as long as the standard deviation of the treatment difference did not exceed 0.2 litres. Allowing for subject withdrawals, in order to have 42 children completing all three treatment periods (and therefore to be included in the per-protocol analysis), we aimed to recruit a total of 48 patients. A pre-specified per protocol statistical analysis plan was followed and applied to the data from those children who completed all three treatment periods. The analysis
focused on two separate pairwise comparisons of the treatments: mannitol alone versus rhDNase alone, and mannitol plus rhDNase together versus rhDNase alone. A regression model compared within-subject differences between outcomes at the end of each treatment period (Y1-Y0), with adjustment for differences in the same outcome measure at the beginning of these periods (X1-X0). The regression equation is:

\[(Y1-Y0) = a + b(X1-X0)\]

where a, the intercept term, is the adjusted difference in mean outcome between the two treatments being compared. The ordinary least squares method was used to estimate a and b; the assumption of normally distributed residuals was investigated graphically for each model and found to be satisfied.

FEV1 and the secondary outcome measures were analysed on a measurement scale and the results presented as mean differences. In addition, the primary outcome, FEV1, was analysed on a log scale, and the results presented as percentage differences between treatments. Pulmonary exacerbations were compared between treatments using McNemar’s test. p < 0.05 was considered statistically significant throughout.

Results

Forty-five children were recruited to the study, thirty-eight of whom underwent an airway challenge with inhaled mannitol. Seven were not enrolled due to clinical instability. Nine children had a positive challenge test with mannitol. One further challenge was abandoned due to nausea. 28 subjects were therefore included in the
main study and randomly allocated to a treatment sequence. 8 children withdrew during the study. The primary reason sited was troublesome cough in 6/8 (in whom 3 there was evidence of a chest exacerbation at the time of withdrawal), nausea in 1/8 and treatment burden in 1/8. Treatment burden was reported as a contributory factor in a further 2/8 patients in whom cough was the main problem. The per-protocol analysis presented here is based on the 20 children who completed all three treatment periods (Figure 1).

The mean age was 13.2 years (SD 2.4 years), and 14 (70%) were girls. The mean baseline FEV$_1$ was 1.67 litres (SD 0.50 litres) (mean 64% of predicted FEV$_1$; SD 10%). (Table 1) The adequacy of the washout periods in preventing carry-over was assessed by comparing, in turn, the pre-treatment assessments for periods two and three to that for period one. We found no evidence of carry-over effects between treatment periods.

Nineteen children returned treatment packs and vials. Adherence was greater than 70% in 14/19 patients with mannitol, 13/19 with rhDNase and 17/19 with a combination of both treatments. There was therefore no statistically significant difference in adherence in the different treatment groups.

The mean percentage change in FEV$_1$ over each treatment period (final FEV$_1$ minus initial FEV$_1$ expressed as a percentage of initial FEV$_1$) is shown in Table 2. The mean FEV$_1$ between the start and end of the treatment period increased with mannitol alone (0.11 litres (6.7%), 95% CI 0.00 to 0.23 litres, p=0.055), with rhDNase alone (0.12 litres 7.2%), 95% CI 0.01 to 0.22 litres, p=0.03), but not with mannitol and rhDNase combined (0.03 litres, 95% CI –0.12 to +0.18 litres, p=0.67). The relative effects of treatments were also calculated as the mean difference in post-treatment outcome, adjusted for any start of treatment period difference. Comparing mannitol alone to
rhDnase alone, there was a non-statistically significant trend for a higher FEV_{1} (0.05 litres, 2.8%) with mannitol (95% CI -4.2% to 10.4%, p=0.42).

We found marked variation between individuals in response to mannitol and rhDNase and the percentage change in FEV_{1} with mannitol alone and rhDNase alone for individual children is shown in Figure 2.

Whilst an improvement in FVC was apparent following treatment with rhDNase alone and mannitol alone, there was evidence of a trend towards greater improvement with the mannitol (p=0.053, Table 3). There was no change in FVC following treatment with mannitol and rhDNase. There was no evidence of a difference between treatment groups for any of the other secondary outcome measures.

Discussion

We report that three months treatment with inhaled mannitol was as effective as rhDNase (the current best established mucolytic therapy), with each treatment resulting in a 7% increase in FEV_{1} from baseline. The combination of the two therapies was not useful. There was marked individual variation in response to both treatments with wide confidence intervals for increase in FEV_{1}. 9/20 children had an improvement of more than 10% in FEV_{1} with mannitol and 8/20 with rhDNase, undoubtedly clinically significant improvements. Figure 2 also suggests that patients who do not respond to rhDNase may derive benefit from inhaled mannitol. The 3 patients with the largest response to a combination of mannitol and rhDnase, had modest responses to the individual treatments. There was no statistically significant difference in any of the secondary outcome measures. In particular there was no evidence of increased growth of *Pseudomonas aeruginosa* in sputum in the mannitol treated group.
This study represents the first therapeutic trial of mannitol in children with CF. Bronchoconstriction and cough significantly reduced the tolerability of mannitol and this contributed to the high study attrition rate (47%) and smaller numbers completing the study. 9/38 (24%) of subjects were withdrawn due to a positive airway challenge. The majority of patients reported significant cough during administration of mannitol, both with the initial airway challenge & subsequent regular administration. 6 of the 8 children who subsequently withdrew from the study sited cough associated with administration of mannitol as the main reason. Both these problems occurred despite pre-treatment with bronchodilators. The study achieves 61% power with 20 children completing the study.

A comparative therapeutic trial would ideally adopt a double-bind design. This was impossible in the current study as the presentation and mode of delivery of the two therapies is very different. Mannitol is a dry-powder packaged in gelatine capsules which are inhaled via a breath-activated inhaler device (Osmohaler). It tastes sweet and is administered twice a day. rhDNase is inhaled as an aerosol delivered via a nebuliser device once a day. There has been much debate on the appropriateness of a crossover design to examine an intervention that potentially affects the natural history of a disease. [23-25] Two recent trials of azithromycin and rhDNase therapy in children with CF have successfully employed a crossover design. [3,23] The main disadvantage with crossover trials is related to potential treatment interactions over the study period, and in particular carry-over effects. This is overcome by including sufficiently long washout periods between treatment blocks. There was no evidence of carry-over effect in the current study.

Outcome measures in trials of CF therapy are an area of great interest currently. [26-28] FEV₁ currently remains the best established and most objective measure of
clinical benefit associated with a therapeutic intervention in CF. It might not be the most appropriate outcome measure for a potentially bronchoconstricting therapy however. Alternatives such as lung clearance index (LCI) or radiolabelled measures of mucociliary clearance may need consideration in future trials.

An upper limit for FEV$_1$ of 70% predicted value was chosen for two main reasons. Firstly, a baseline FEV$_1$ approaching 100% of predicted value is unlikely to allow a clear statistically measurable change in FEV$_1$ associated with each treatment regimen. Secondly, in order to justify commencement of rhDNase therapy, it was felt that patients should have at least moderate lung disease (reflected in the chosen cut-off of 70%). Recently, rhDNase has been increasingly used in patients with milder chest phenotypes [29] and an increase in the upper limit for baseline FEV$_1$ may be justifiable. With a therapy that potentially causes acute bronchoconstriction, a safe lower limit for FEV$_1$ of 40% of predicted value was chosen.

The dose of mannitol utilized for the airway challenge has been previously reviewed [22]. It may be that utilising a slightly lower cumulative dose of mannitol for the airway challenge will allow more children to be recruited to a therapeutic trial. Similarly the therapeutic dose of mannitol employed in the current study is based largely on data from studies in adults. The pilot study on MCC in adult CF patients used 300mg of mannitol [18] and the recent short-term safety and efficacy study used 420mg. [19] More recent evidence in adults with bronchiectasis suggests there is a dose response to at least 480mg. [30] It may be that, in children, a lower dose may have resulted in less coughing and improve adherence.

The increase in FEV$_1$ with rhDNase is similar to that reported previously [3] and that for mannitol was approximately equivalent. The lack of evidence for increase in sputum infection with *Pseudomonas aeruginosa* is important as it has been suggested
that mannitol could theoretically act as a bacterial energy source. The initial pilot study reported mannitol was safe and well-tolerated. [19] The current trial suggests that it may cause more bronchoconstriction and troublesome cough than previously reported. Jacques et al. also suggested that a combination of mannitol and rhDNase may be better than either therapy alone. This is not supported by our findings but larger numbers are required to further study this effect. We can only speculate as to why the combination of the two mucolytics was not beneficial. Our results suggest adherence is not an issue, although it is possible that the burden of two inhaled therapies resulted in less than a full treatment dose being taken. Alternatively the combination of agents may have resulted in too great a reduction in airway mucus viscosity so that cilia were unable to function effectively (the mucociliary escalator would not clear pure water for example).

Given the potential problems of tolerability with mannitol in our children, recruiting subjects to future studies may depend on altering certain aspects of our study design. It may be appropriate to recruit children with milder chest disease (particularly if mannitol is seen as potentially beneficial early in the disease process). A lower dose of mannitol may improve tolerability. It would be of interest to include newer outcome measures in any future therapeutic trial. The mechanism for the apparent mutual antagonism of mannitol and rhDNase combined also requires further study. The effect of mannitol on airway inflammation and sputum rheology remains uncertain and interesting areas for future research.

In summary, we have shown in the first therapeutic trial of inhaled mannitol in children with CF that it is potentially at least as effective as rhDNase. The combination of both therapies was not beneficial. There is marked variation in response to both therapies and in addition to HS and individuals who not benefit from
either rhDNase or HS may warrant a trial of inhaled mannitol. Cough and bronchoconstriction may limit the tolerability of mannitol for some children.
REFERENCES

1. Fuchs H, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. *N Engl J Med* 1994;331:637-642

2. McCoy K, Hamilton S, Johnson CAC. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. *Chest* 1996;153:1914-1917

3. Suri R, Metcalfe C, Lees B, Grieve R, Flather M, Normand C, et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomized trial. *Lancet* 2001;353:1316-1321

4. Paul K, Rietschel E, Ballmann M, Griese M, Worlitzsch D, Shute J, Chen C, Schink T, Doring G, van Koningsbruggen S, Wahn U, Ratjen F. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. *Am J Respir Crit Care Med* 2004;169:719-725

5. Ranasinha C, Assoufi B, Shak S, Christiansen DH, Fuchs H, Empey D, et al. Efficacy and safety of short-term administration of aerosolized recombinant human DNase I in adults with stable stage cystic fibrosis. *Lancet* 1993;342:199-202

6. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. *Cell* 1998;95:1005-1015.
7. Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. *Eur Respir J* 2004;23:146-158.

8. Boucher RC. Evidence for airway surface dehydration as the initiating event in CF airway disease. *J Intern Med* 2007;261:5-16.

9. Boucher RC. Cystic fibrosis: a disease of vulnerability to airway surface dehydration. *Trends Mol Med* 2007;13:231-240.

10. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. *N Engl J Med* 2006;354:241-250.

11. Elkins MR, Bye PT. Inhaled hypertonic saline as a therapy for cystic fibrosis. *Curr Opin Pulm Med* 2006;12:445-452.

12. Anderson SD, Brannan J, Spring J, Spalding N, Rodwell LT, Chan K, et al. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. *Am J Respir Crit Care Med* 1997;156:758-765.

13. Brannan JD, Anderson SD, Perry CP, Freed-Martens R, Lassig AR, Charlton B. The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline. *Respir Res* 2005;6:144.

14. Barben J, Roberts M, Chew N, Carlin JB, Robertson CF. Repeatability of bronchial responsiveness to mannitol dry powder in children with asthma. *Pediatr Pulmonol* 2003;36:490-494.
15. Daviskas E, Anderson SD, Brannan JD, Chan HK, Eberl S, Bautovich G. Inhalation of dry-powder mannitol increases mucociliary clearance. *Eur Respir J* 1997;10:2449-2454.

16. Daviskas E, Anderson SD, Eberl S, Chan HK, Bautovich G. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. *Am J Respir Crit Care Med* 1999;159:1843-1848.

17. Daviskas E, Anderson SD, Eberl S, Chan HK, Young IH. The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis. *Chest* 2001;119:414-421.

18. Robinson M, Daviskas E, Eberl S, Baker J, Chan HK, Anderson SD, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. *Eur Respir J* 1999;14:678-685.

19. Jacques A, Daviskas E, Turton JA, McKay K, Cooper P, Stirling RG, Robertson CF, Bye PT, Souef PN, Shadbolt B, Anderson SD, Charlton B. Inhaled mannitol improves FEV₁ in cystic fibrosis. *Chest* 2008;133:1388-1396.

20. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. *J Pediatr* 1998;132:589-595.

21. Standardization of Spirometry, 1994 Update. American Thoracic Society. *Am J Respir Crit Care Med* 1995;152:1107-1136.
22. Minasian C, Wallis C, Metcalfe C, Bush A. Bronchial provocation testing with dry powder mannitol in children with cystic fibrosis. Pediatr Pulmonol 2008;43:1078-1084

23. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002;360:978-84

24. Southern KW, Smyth RL. Design of clinical trials in CF. Lancet 2003;361:349-350

25. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Author’s reply Lancet 2003;361:350

26. Rosenfeld M. An overview of endpoints for cystic fibrosis clinical trials: one size does not fit all. Proc Am Thorac Soc 2007;4:299-301

27. Mayer-Hamblett N, Bamsey BW, Kronmal RA. Advancing cystic fibrosis measures for the new era of drug development in cystic fibrosis. Proc Am Thorac Soc 2007;4:370-1

28. Suri R, Metcalfe C, Wallis C, Bush A. Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respir Med 2007;101:254-60

29. Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, Wohl ME, Konstan MW, Pulmozyme Early Intervention Trial Study Group. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001;139:813-20
30. Daviskas E, Anderson SD, Eberl S, Young IH. Effects of increasing doses of mannitol on mucus clearance in patients with bronchiectasis. *Eur Resp J* 2008;31:765-772
**TABLE I. Baseline characteristics of study population**

|                             | Analysis sample (n=20) | Randomized (n=28) | Completed challenge (n=38) |
|-----------------------------|------------------------|-------------------|---------------------------|
| Mean age in years (SD)      | 13.2 (2.36)            | 13.3 (2.24)       | 12.5 (2.49)               |
| Mean weight in kg (SD)       | 41.1 (11.2)            | 41.7 (10.6)       | 40.9 (11.5)               |
| Mean height in cm (SD)       | 149 (13.9)             | 151 (13.8)        | 150 (15.9)                |
| Number of females (%)        | 14 (70)                | 18 (64)           | 21 (55)                   |
| Mean FEV₁ in litres (SD)     | 1.67 (0.50)            | 1.80 (0.57)       | 1.76 (0.58)               |
| Mean FEV₁ % predicted (SD)   | 64.4 (10.4)            | 67.2 (12.0)       | 67.5 (11.8)               |

**Sputum microbiology**

- *Pseudomonas aeruginosa*: 4 (22%)
- *Staphylococcus aureus*: 2 (11%)
- *Sternotrophomonas maltophilia*: 2 (11%)
- *Aspergillus fumigatus*: 5 (28%)

¹ Results available for 18 patients in analysis sample
## TABLE 2

Mean percentage change in FEV₁ over 12 week treatment period (final FEV₁ minus initial FEV₁ expressed as a percentage of initial FEV₁)

|                      | Pre-treatment (litres) | Post-treatment (litres) | Change in FEV₁ (litres) (%) | 95% CI      | P*       |
|----------------------|------------------------|-------------------------|-----------------------------|-------------|----------|
| Mannitol alone       | 1.68 (0.60)            | 1.79 (0.63)             | +0.11 (6.7%)                | (0.00, 0.23) | 0.055    |
| RhDNase alone        | 1.59 (0.59)            | 1.70 (0.57)             | +0.12 (7.2%)                | (0.01, 0.22) | 0.029    |
| Mannitol + RhDNase   | 1.65 (0.45)            | 1.68 (0.62)             | +0.03 (1.9%)                | (-0.12, 0.18) | 0.67    |

*p values derived from paired t-tests

**Comparison of mean percentage change in FEV₁ between treatments, adjusted for baseline**

|                      | Pre-treatment (litres) | Post-treatment (litres) | Comparison with rhDNase alone (%) | 95% CI      | P*       |
|----------------------|------------------------|-------------------------|----------------------------------|-------------|----------|
| RhDNase alone        | 1.59 (0.59)            | 1.70 (0.57)             |                                  |             |          |
| Mannitol alone       | 1.68 (0.60)            | 1.79 (0.63)             | +2.8                             | (-4.2 to +10.4) | 0.42    |
| Mannitol + RhDNase   | 1.65 (0.45)            | 1.68 (0.62)             | -4.3                             | (-14.1 to +6.5) | 0.40    |

*p values derived from regression analysis
### TABLE 3

Mean percentage change in FVC & FEF\textsubscript{25-75} between treatments, adjusted for baseline

|                  | Pre-treatment (litres) | Post-treatment (litres) | Comparison with RhDNase alone (litres) | 95% CI          | P*  |
|------------------|------------------------|-------------------------|---------------------------------------|----------------|-----|
| **FVC**          |                        |                         |                                       |                 |     |
| RhDNase alone    | 2.25 (0.79)            | 2.39 (0.74)             |                                       |                 |     |
| Mannitol alone   | 2.37 (0.76)            | 2.54 (0.78)             | +0.14                                 | (–0.00 to +0.29)| 0.053|
| Mannitol + RhDNase | 2.31 (0.61)           | 2.31 (0.81)             | –0.07                                 | (–0.30 to +0.16)| 0.52|
| **FEF\textsubscript{25-75}** |                        |                         |                                       |                 |     |
| RhDNase alone    | 1.12 (0.63)            | 1.17 (0.65)             |                                       |                 |     |
| Mannitol alone   | 1.18 (0.64)            | 1.21 (0.65)             | –0.01                                 | (–0.22 to +0.20)| 0.91|
| Mannitol + RhDNase | 1.18 (0.49)           | 1.26 (0.65)             | +0.03                                 | (–0.18 to +0.25)| 0.76|

*p values derived from regression analysis*
FIGURE 1

Study Profile

67 patients eligible

45 recruited

38 performed airway challenge

22 declined to participate

7 not enrolled (clinically unstable)

9 positive challenges
1 abandoned due to nausea

28 randomised

8 withdrawn due to troublesome cough associated with mannitol administration

20 completed study
Individual patients' changes in FEV\textsubscript{1} (% change in FEV\textsubscript{1} with rhDNase vs. % change in FEV\textsubscript{1} with mannitol)